Epoch Investment Partners Inc. cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 30.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,637 shares of the medical research company’s stock after selling 31,270 shares during the period. Epoch Investment Partners Inc. owned 0.24% of Bio-Rad Laboratories worth $22,109,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. BlackRock Inc. lifted its holdings in Bio-Rad Laboratories by 0.3% in the third quarter. BlackRock Inc. now owns 1,867,884 shares of the medical research company’s stock worth $584,627,000 after buying an additional 6,197 shares during the period. Alliancebernstein L.P. lifted its holdings in Bio-Rad Laboratories by 4.2% in the third quarter. Alliancebernstein L.P. now owns 268,138 shares of the medical research company’s stock worth $83,925,000 after buying an additional 10,691 shares during the period. Bank of New York Mellon Corp lifted its holdings in Bio-Rad Laboratories by 6.6% in the third quarter. Bank of New York Mellon Corp now owns 231,356 shares of the medical research company’s stock worth $72,412,000 after buying an additional 14,408 shares during the period. Columbus Circle Investors lifted its holdings in Bio-Rad Laboratories by 54.1% in the third quarter. Columbus Circle Investors now owns 129,183 shares of the medical research company’s stock worth $40,433,000 after buying an additional 45,344 shares during the period. Finally, Canada Pension Plan Investment Board increased its stake in shares of Bio-Rad Laboratories by 34.2% during the third quarter. Canada Pension Plan Investment Board now owns 125,900 shares of the medical research company’s stock valued at $39,405,000 after purchasing an additional 32,100 shares in the last quarter. Institutional investors and hedge funds own 62.37% of the company’s stock.
A number of equities analysts have weighed in on the stock. Barclays decreased their target price on shares of Bio-Rad Laboratories from $345.00 to $315.00 and set an “equal weight” rating for the company in a research note on Friday, November 2nd. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research note on Monday, November 12th. Morgan Stanley assumed coverage on shares of Bio-Rad Laboratories in a research note on Thursday, September 20th. They set an “equal weight” rating and a $335.00 target price for the company. Goldman Sachs Group assumed coverage on shares of Bio-Rad Laboratories in a research note on Wednesday, October 17th. They set a “buy” rating and a $350.00 target price for the company. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 target price on shares of Bio-Rad Laboratories in a research note on Monday, September 24th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $338.43.
Shares of NYSE BIO opened at $256.23 on Friday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $231.00 and a fifty-two week high of $345.15. The company has a market cap of $7.88 billion, a price-to-earnings ratio of 50.38, a price-to-earnings-growth ratio of 3.20 and a beta of 1.09. The company has a quick ratio of 3.16, a current ratio of 4.49 and a debt-to-equity ratio of 0.09.
Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, November 1st. The medical research company reported $0.91 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.16 by ($0.25). Bio-Rad Laboratories had a net margin of 55.13% and a return on equity of 3.72%. The business had revenue of $545.10 million for the quarter, compared to the consensus estimate of $541.23 million. During the same period in the prior year, the business posted $0.91 EPS. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 5.47 EPS for the current year.
WARNING: “Bio-Rad Laboratories, Inc. (BIO) Shares Sold by Epoch Investment Partners Inc.” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/12/08/bio-rad-laboratories-inc-bio-shares-sold-by-epoch-investment-partners-inc.html.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Story: Rule of 72
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.